[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355767-105":59,"doc-detail-355767-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","t-cell-engaging-bispecific-antibodies-for-myeloid-malignancies-targets-formats-and-clinical-challenges","T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges","","T cell-engaging bispecific antibodies (T-BsAbs) are transforming immunotherapy for hematologic malignancies, yet myeloid cancers such as acute myeloid leukemia face key limitations. This review surveys current development for myeloid diseases, covering target antigen selection, antibody engineering formats, and reported clinical trial outcomes. It analyzes how strategies aim to improve efficacy, mitigate myelotoxicity, and reduce on-target, off-tumor effects on normal hematopoietic cells. It also considers combination approaches and future target-discovery priorities, including neoantigen- and multi-target frameworks.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/t-cell-engaging-bispecific-antibodies-for-myeloid-malignancies-targets-formats-and-clinical-challenges/355767/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/t-cell-engaging-bispecific-antibodies-for-myeloid-malignancies-targets-formats-and-clinical-challenges/355767.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes T cell-engaging bispecific antibodies challenging in myeloid malignancies?","Question",{"text":112,"@type":113},"They can cause myelotoxicity due to limited target specificity, including on-target, off-tumor effects affecting hematopoietic stem and progenitor cells. Additional issues include cytokine release syndrome, ICANS, antigen loss, and immune exhaustion.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the review describe current clinical progress and limitations for AML immunotherapy?",{"text":117,"@type":113},"It notes that AML and MDS lack FDA-approved T-BsAbs, while other targeted options exist but face drawbacks such as relapse and treatment-related toxicity. It highlights that long-term outcomes remain poor despite chemotherapy, transplantation, and newer targeted agents.",{"name":119,"@type":110,"acceptedAnswer":120},"What antibody engineering and combination strategies are emphasized for improving safety and efficacy?",{"text":121,"@type":113},"The review discusses bispecific formats designed to enhance efficacy while reducing toxicity, and emerging therapeutic combinations with agents such as hypomethylating drugs or chemotherapy. It also points to future needs for AML-specific targets, neoantigen platforms, and multi-target or co-stimulatory approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355767,1790665233,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","ll  \nOPEN ACCESS  \nReview  \nT cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges  \nSophie Paczesny,1,* Sonali P. Barwe,2 Anilkumar Gopalakrishnapillai,2 and Nai-Kong V. Cheung3  \n1Hollings Cancer Center and Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA  \n2Nemours Children’s Hospital, Lisa Dean Moseley Foundation Institute of Cancer and Blood Disorders, Wilmington, DE, USA  \n3Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, NY, USA  \n*Correspondence: [paczesns@musc.edu](paczesns@musc.edu)[ ](paczesns@musc.edu)[https://doi.org/10.1016/j.xcrm.2026.102772](https://doi.org/10.1016/j.xcrm.2026.102772)  \nSUMMARY  \nT cell-engaging bispecific antibodies (T-BsAbs) have revolutionized immunotherapy for hematologic malignancies, showing promise in lymphoid cancers and myeloma. However, their application in myeloid malignancies like acute myeloid leukemia (AML) faces challenges due to myelotoxicity and limited target specificity. Here, we review the current landscape ofT-BsAb development for myeloid diseases, detailing target antigens, antibody engineering strategies, and clinical trial outcomes. We discuss advances in bispecific antibody formats designed to enhance efficacy and reduce toxicity, alongside emerging therapeutic combinations. Our synthesis highlights the complexity of targeting myeloid malignancies while sparing normal hematopoietic cells. These insights underscore the potential of refined T-BsAb approaches to improve treatment specificity and efficacy in AML and related disorders, informing future therapeutic strategies and clinical development.  \nINTRODUCTION  \nAcute myeloid leukemia (AML) is an aggressive hematologic malignancy defined by uncontrolled proliferation of abnormal myeloid blasts in the bone marrow, while myelodysplastic syndrome (MDS) comprises disorders of ineffective hematopoiesis with \u003C20% blasts; although MDS can progress to AML, this occurs only in a subset of patients. Globally, AML incidence has nearly doubled over the past three decades, reaching 185,723 cases and 131,579 deaths in 2023,1 ,2 with 22,010 new US cases and 11,090 deaths projected for 2026.3 The economic burden is substantial, with an average US treatment episode costing approximately $400,000 .4  \nFor decades, intensive cytarabine-anthracycline chemotherapy was the standard of care, inducing remission in many but curing only a minority, as most patients relapse.5 Over the past decade, hypomethylating agents (HMAs) and targeted inhibitors of FLT3, IDH, and BCL-2 have expanded therapeutic options and improved response rates.6 Current guidelines emphasize individualized strategies incorporating age, cytogenetic and molecular risk, and minimal residual disease (MRD) assessment.7 ,8 Despite progress, relapse and treatment-related toxicity remain major challenges, and even with advances in chemotherapy and hematopoietic cell transplantation (HCT), longterm outcomes remain poor, with a 5-year survival of 31 .9% .3  \nImmunotherapy has emerged as a complementary approach, including monoclonal antibodies, Fc-enhanced antibodies, antibody-drug conjugates (ADCs), and T cell-engaging bispecific antibodies (T-BsAbs),9 as well as CAR-T10 and CAR-natural killer  \n(NK) cell therapies. T-BsAbs and CAR-T cells redirect T cells to AML blasts, though they differ in manufacturing complexity and activation requirements. These modalities are increasingly combined with HMAs or chemotherapy to enhance efficacy.  \nHowever, targeting classical myeloid antigens such as CD33 and CD123 has been limited by on-target, off-tumor toxicity affecting hematopoietic stem and progenitor cells (HSPCs), leading to severe cytopenias.11 Additional barriers include cytokine release syndrome (CRS), immune-effector-cell-associated neurotoxicity syndrome (ICANS), antigen loss, clonal evolution, an immunosuppressive tumor microenvironment, and T cell exh","cbCaiuYLJOtQGcdb","https://ap.wps.com/l/cbCaiuYLJOtQGcdb","pdf",2796160,18,"English","# Summary\n# Introduction\n## Burden and current standard-of-care\n## Emerging immunotherapies and T-BsAbs\n## Barriers to effective targeting in myeloid malignancies\n# Target antigens under investigation for bispecific antibody development in myeloid malignancies","[{\"question\":\"What makes T cell-engaging bispecific antibodies challenging in myeloid malignancies?\",\"answer\":\"They can cause myelotoxicity due to limited target specificity, including on-target, off-tumor effects affecting hematopoietic stem and progenitor cells. Additional issues include cytokine release syndrome, ICANS, antigen loss, and immune exhaustion.\"},{\"question\":\"How does the review describe current clinical progress and limitations for AML immunotherapy?\",\"answer\":\"It notes that AML and MDS lack FDA-approved T-BsAbs, while other targeted options exist but face drawbacks such as relapse and treatment-related toxicity. It highlights that long-term outcomes remain poor despite chemotherapy, transplantation, and newer targeted agents.\"},{\"question\":\"What antibody engineering and combination strategies are emphasized for improving safety and efficacy?\",\"answer\":\"The review discusses bispecific formats designed to enhance efficacy while reducing toxicity, and emerging therapeutic combinations with agents such as hypomethylating drugs or chemotherapy. It also points to future needs for AML-specific targets, neoantigen platforms, and multi-target or co-stimulatory approaches.\"}]","T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges | PDF",1790120837,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b93446f3afe788075212de067fe204c.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90aa17e286582e8e2b3f0a5aa002d1c2.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f34b5ee3441af0fead782d8dfd2be2be.webp",981,755,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e35922da1d4afd98814e00105f2812b7.webp",980,754]